Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biopharmaceutical company with a market capitalization of $131.2 billion, has been making significant strides in the treatment of cystic fibrosis (CF) ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

BlackDiamond Wealth Management LLC now owns 12,080 shares of the financial services provider’s stock valued at $2,896,000 after purchasing an additional 354 shares during the last quarter.

BlackDiamond Wealth Management LLC now owns 12,080 shares of the financial services provider’s stock valued at $2,896,000 after purchasing an additional 354 shares during the last quarter.

IBI354 targets platinum-resistant ovarian cancer with HER2 expression, showing promising antitumor activity and safety in early trials. The phase 1/2 study reported a 40.2% objective response rate and ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...